Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Creon

- PMLiVE

Actavis to buy Allergan for $66bn

Ends Valeant’s pursuit of Botox maker

- PMLiVE

Allergan ‘close’ to $60bn takeover agreement with Actavis

If successful the negotiations would scupper Valeant's hostile bid

- PMLiVE

Actavis ‘considering’ white knight bid for Allergan

Wall Street Journal says Irish pharma company set to challenge Valeant's bid

- PMLiVE

Valeant dangles higher bid in front of Allergan shareholders

Proposes $200 a share deal

- PMLiVE

Orphan drugs lead CHMP recommendations

Clinuvel's Scenesse is first drug set for European approval to treat rare intolerance to sunlight

- PMLiVE

Valeant adds Jeffrey Ubben to board

CEO of ValueAct supports takeover of Allergan

- PMLiVE

EMA wants to embed patient viewpoint within drug assessment

Will pilot CHMP benefit-risk evaluation project

- PMLiVE

Pharma and med tech companies form eye health group

The Industry Vision Group wants the NHS to make eye care a priority

- PMLiVE

New eye indication for Allergan’s Ozurdex

EU approval extends the drug's use to diabetic macular oedema

- PMLiVE

Allergan agrees to shareholder meeting on Valeant bid

Pershing Square Capital convinces shareholders to request consultation

Allergan appoints financial head

Jim Hindman named chief financial officer

- PMLiVE

Valeant extends Allergan bid deadline to end of 2014

Acquisition saga carries on beyond original August 15 deadline

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links